Medical Patent News

RSS

Aventix Pharma takes over key patents for innovative screening tool for treatments for cystic fibrosis

The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company Axentis Pharma AG.

26 Jun 2008

India's patent office rejects Boehringer's application for pediatric antiretroviral

India's Patent Office in New Delhi earlier this month rejected German drug maker Boehringer Ingelheim's application for a pediatric version of the antiretroviral drug nevirapine, consequently allowing local generic pharmaceutical companies such as Aurobindo and Cipla to continue marketing low-cost versions of the medicine in the domestic market, the Business Standard reports.

24 Jun 2008

Alchemia granted first two patents in the "Synthetic Heparin Oligosaccharide" family of patents

Alchemia Ltd. has announced the granting of the first two patents in the "Synthetic Heparin Oligosaccharide" family of patents.

23 Jun 2008

AutoGenomics issued European patent for Human papillomavirus

AutoGenomics has announced that it has been issued a key European patent for Human papillomavirus.

19 Jun 2008

Ranbaxy and Pfizer settle on Lipitor patent litigation

Ranbaxy Laboratories Limited (Ranbaxy), announced today that it has entered into an agreement with Pfizer Inc. to settle most of the patent litigation worldwide involving Atorvastatin (Lipitor), the world's most-prescribed cholesterol-lowering medicine.

19 Jun 2008

Peregrine Pharmaceuticals awarded two new U.S. patents for targeted anti-aminophospholipid agents

Peregrine Pharmaceuticals, Inc. today reported the issuance of two U.S. patents that significantly broaden the company's intellectual property leadership in the field of targeted anti-aminophospholipid agents.

16 Jun 2008

VistaGen Therapeutics announces new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells

VistaGen Therapeutics, Inc., a biotechnology company using leading-edge embryonic stem cell (ES Cell) technologies for predictive toxicology and drug discovery, has announced new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells. VistaGen has exclusive rights for commercial use in its ES Cell-based tools platform for drug discovery and development.

16 Jun 2008

Breakthrough in understanding tumor immune therapy

Researchers from the Tubingen University, Department of Dermatology, uncovered an entirely new understanding on how the immune system may control tumor development.

11 Jun 2008

EntreMed receives new patent for 2-Methoxyestradiol analogs

EntreMed, Inc. has announced the issuance of U.S. Patent No. 7,371,741 covering analogs of 2- methoxyestradiol (2ME2).

11 Jun 2008

Mylan wins generic Prilosec patent litigation

Mylan Inc. has announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a May 2007 District Court ruling stating that Mylan's 10 mg and 20 mg Omeprazole delayed-release capsules do not infringe patents asserted against Mylan by AstraZeneca.

11 Jun 2008

Barr confirms patent challenge of Prevacid SoluTab tablets

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by TAP Pharmaceuticals Inc. in connection with its Prevacid SoluTab Delayed-Release Orally Disintegrating Tablets (lansoprazole), 15mg and 30mg.

11 Jun 2008

Telik announces patents on TELINTRA compounds

Telik, Inc. announced today that the European Patent Office has issued notices of allowance for two applications covering new compounds related to one of Telik's lead clinical candidates, TELINTRA.

11 Jun 2008

FDA grants pediatric exclusivity for UCB's Keppra

UCB has announced that the US Food and Drug Administration (FDA) has granted pediatric exclusivity for Keppra (levetiracetam). The decision was based on pediatric data submitted to the FDA following a written request in 2001.

8 Jun 2008

Mylan confirms Azor patent challenge

Mylan Inc. today confirmed that its majority-owned subsidiary, Matrix Laboratories Ltd., has been sued by Daiichi Sankyo in connection with Amlodipine Besylate/Olmesartan Medoxomil Tablets, 5 mg/20 mg, 10 mg/20 mg, 5 mg/40 mg and 10 mg/40 mg, the generic version of Daiichi Sankyo's Azor Tablets.

4 Jun 2008

Skinvisible granted patent in Australia for polymer delivery system

Skinvisible, Inc. the developers of Invisicare, a polymer delivery system that enhances topically applied products, has been granted a comprehensive patent in Australia.

3 Jun 2008

Cephalon files patent infringement case against Watson Pharmaceuticals

Cephalon, Inc. today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon product FENTORA(R) (fentanyl buccal tablet) [C-II].

3 Jun 2008

DialysisPPO files provisional patent for dialysis cost containment

DialysisPPO, a Pennsylvania Corporation providing cost containment solutions to the health plan market, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering its business method that enables health plans to significantly lower their exposure to the high cost of dialysis services while simultaneously improving the benefits to plan participants.

2 Jun 2008

U.S. Patent Office confirms second of four Viread patents

Gilead Sciences, Inc. has announced that the U.S. Patent & Trademark Office (PTO) has completed the second of four reexamination proceedings and has confirmed the patentability of U.S. Patent No. 5,922,695, which covers the composition of matter for Viread (tenofovir disoproxil fumarate). On May 20, Gilead announced that the U.S. PTO confirmed the patentability of U.S. Patent No. 6,043,230.

2 Jun 2008

Novel approach to drug insolubility strengthens PolyTherics patent estate

Polytherics Ltd, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy that specialises in the targeted application of polymers to biopharmaceuticals, has announced the grant of a European patent on the application of polymer complexation technology to improve drug efficacy.

28 May 2008